Troels Koch has >20 years of experience in the international life science and biopharmaceutical industry. Founder of several biotech companies of which Exiqon A/S and Santaris Pharma A/S are the most commonly known. Santaris Pharma A/S was successfully exited in August 2014 – acquired by Roche – and Exiqon A/S was acquired in 2016 by Qiagen. He has been positioned in company management teams and taken part in all aspects of executive decision making: Company strategy, VC fundraising, deal makings, partnering, IP strategy & prosecution, drug discovery and R&D. He pioneered LNA therapeutics and is working on keeping LNA antisense science and technology at an international lead position. He co-founded Inexos Therapeutics in 2019 and is presently CTO, SVP Science & Technology.
Troels has worked with RNA therapeutics for 20 years and taken an active role in all steps of oligonucleotide drug discovery and development. He has built R&D organizations up to 75 co-workers, held 100+ invited presentations at international conferences and is author of 80+ peer reviewed publications.